Saturday, July 11, 2026

Drug profile · INN

teplizumab-mzwv

teplizumab-mzwv (TZIELD) is a t-cell surface glycoprotein cd3 epsilon chain other. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 3
Drug details — teplizumab-mzwv

Quick answer

teplizumab-mzwv (TZIELD) is a t-cell surface glycoprotein cd3 epsilon chain other. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN teplizumab-mzwv
Brand TZIELD
Mechanism T-cell surface glycoprotein CD3 epsilon chain other
Target T-cell surface glycoprotein CD3 epsilon chain
Route INJECTION
Formulation INJECTABLE

Mechanism of action

T-cell surface glycoprotein CD3 epsilon chain other

Primary target: T-cell surface glycoprotein CD3 epsilon chain

Approval history

Authority Status Date
FDA approved

Recent coverage

Related & competitor drugs

  1. teplizumab Alimentary tract and metabolism (A10)
  2. visilizumab T-cell surface glycoprotein CD3 epsilon chain inhibitor

Frequently asked questions

What is teplizumab-mzwv?

teplizumab-mzwv (TZIELD) is a t-cell surface glycoprotein cd3 epsilon chain other. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for teplizumab-mzwv?

TZIELD is a marketed brand name for teplizumab-mzwv. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of teplizumab-mzwv?

teplizumab-mzwv has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.